April 9, 2024
View Full PaperImpact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)
Key Points
Key points are not available for this paper at this time.
Abstract
To evaluate the effects of fenebrutinib on MRI outcomes and the ability of fenebrutinib to enter cerebrospinal fluid (CSF) in the ongoing Phase II study FENopta (NCT05119569).